Clear All
12611 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
72579-0022-08 72579-0022 Sonrotoclax BEQALZI 80.0 mg/1 Chemotherapy Enzyme Inhibitor BCL-2 Oral Aug 31, 2026 In Use
72579-0015-04 72579-0015 Sonrotoclax BEQALZI 1.0 mg/1, 5.0 mg/1, 20.0 mg/1, 80.0 mg/1 Chemotherapy Enzyme Inhibitor BCL-2 Oral Aug 31, 2026 In Use
43598-0518-21 43598-0518 Pomalidomide Pomalidomide 3.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Aug 31, 2026 In Use
72579-0025-01 72579-0025 Sonrotoclax BEQALZI 20.0 mg/1 Chemotherapy Enzyme Inhibitor BCL-2 Oral Aug 31, 2026 In Use
72579-0025-02 72579-0025 Sonrotoclax BEQALZI 20.0 mg/1 Chemotherapy Enzyme Inhibitor BCL-2 Oral Aug 31, 2026 In Use
84651-0200-90 84651-0200 Taletrectinib IBTROZI 272.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ROS1, TRKA, TRKB, TRKC Oral Sep 1, 2026 In Use
72205-0394-01 72205-0394 CLOFARABINE CLOFARABINE 1.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Sep 1, 2026 In Use
00781-2354-27 00781-2354 Pomalidomide Pomalidomide 1.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sep 1, 2026 In Use
00781-2366-27 00781-2366 Pomalidomide Pomalidomide 3.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sep 1, 2026 In Use
50633-0230-01 50633-0230 Naxitamab DANYELZA 40.0 mg/10mL Immunotherapy Monoclonal Antibody GD2 Intravenous Sep 1, 2026 In Use
42658-0024-01 42658-0024 Fludarabine Phosphate Fludarabine Phosphate 25.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Sep 1, 2026 In Use
00781-2358-27 00781-2358 Pomalidomide Pomalidomide 2.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sep 1, 2026 In Use
00781-2369-27 00781-2369 Pomalidomide Pomalidomide 4.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sep 1, 2026 In Use
72205-0178-91 72205-0178 Pomalidomide Pomalidomide 3.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sep 2, 2026 In Use
72205-0179-91 72205-0179 Pomalidomide Pomalidomide 4.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sep 2, 2026 In Use
72205-0178-21 72205-0178 Pomalidomide Pomalidomide 3.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sep 2, 2026 In Use
72205-0179-21 72205-0179 Pomalidomide Pomalidomide 4.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sep 2, 2026 In Use
72205-0177-91 72205-0177 Pomalidomide Pomalidomide 2.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sep 2, 2026 In Use
72205-0177-21 72205-0177 Pomalidomide Pomalidomide 2.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sep 2, 2026 In Use
00310-0075-95 00310-0075 Camizestrant ETCAMAH 75.0 mg/1 Hormonal Therapy Estrogen Receptor Antagonist ERα Oral Sep 4, 2026 In Use
21586-0211-02 21586-0211 Ifosfamide for Injection Ifosfamide 1.0 g/1 Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Sep 4, 2026 In Use
17856-0815-05 17856-0815 Prednisolone Sodium Phosphate Prednisolone Sodium Phosphate 15.0 mg/5mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Sep 4, 2026 In Use
83616-0107-11 83616-0107 Vusolimogene oderparepvec-wtpg Tudriqev 10000000.0 [PFU]/mL Immunotherapy Oncolytic Viral Therapy GALV-GP-R, GM-CSF INTRATUMOR Sep 4, 2026 In Use
00310-0075-01 00310-0075 Camizestrant ETCAMAH 75.0 mg/1 Hormonal Therapy Estrogen Receptor Antagonist ERα Oral Sep 4, 2026 In Use
83616-0106-11 83616-0106 Vusolimogene oderparepvec-wtpg Tudriqev 1000000.0 [PFU]/mL Immunotherapy Oncolytic Viral Therapy GALV-GP-R, GM-CSF INTRATUMOR Sep 4, 2026 In Use

Found 12611 results — Export these results